Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS
NCT ID: NCT05212051
Last Updated: 2022-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
120 participants
INTERVENTIONAL
2021-12-10
2023-01-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA
NCT05242588
A Clinical Study of JS005 in Patients With Ankylosing Spondylitis
NCT06250062
Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)
NCT05861102
A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)
NCT07261644
A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
NCT05303285
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. JS005 150mg Cohort: JS005 150 mg or placebo treatment(JS005:Placrbo=3:1) s.c. prefilled syringe (PFS) on Week 0, 1, 2, 3, 4,8 and 12
2. JS005 300mg Cohort: JS005 300 mg or placebo treatment(JS005:Placrbo=3:1) s.c. PFS on Week0, 1, 2 ,3, 4,8,and 12 3 .JS005 450mg Cohort: JS005 450 mg or placebo treatment(JS005:Placrbo=3:1) s.c. PFS on Week0, 1, 2 ,3, 4,8,and 12 Based on the clinical judgment of disease activity by the investigator and the patient, background medications, such as NSAIDs and DMARDs, may have been modified or added to treat signs and symptoms of AS from Week 16 on.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
JS005 150 mg
30 patients will be enrolled in this arm.
JS005
30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Placebo 150 mg
10 patients will be enrolled in this arm.
Placebo
10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
JS005 300 mg
30 patients will be enrolled in this arm.
JS005
30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Placebo 300 mg
10 patients will be enrolled in this arm.
Placebo
10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
JS005 450 mg
30 patients will be enrolled in this arm.
JS005
30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Placebo 450
10 patients will be enrolled in this arm.
Placebo
10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JS005
30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Placebo
10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Voluntarily participate in this clinical trial and sign the informed consent form.
3. Male or female aged between 18 and 65 years (both inclusive) at the time of signing informed consent. Female subjects of childbearing age are required to have a confirmed negative result of urine and/or serum pregnancy test performed within 3 days before randomization and agree to use reliable contraceptive measures during the study; Male patients and their female partners of childbearing age must agree to use reliable contraception during the study.
4. Patients meet at least one of the following: 1) have an inadequate or ineffective response to NSAIDs, 2) have been intolerant to at least one dose of NSAIDs, 3) have contraindications to NSAIDs therapy. Inadequate or ineffective response to NSAIDs is defined as no remission after continuous treatment with standard doses of at least 2 NSAIDs for a total of no less than 4 weeks and no less than 2 weeks for each NSAID.
5. Patients regularly taking NSAIDs as part of their AS therapy are required to maintain a stable dose for at least 2 weeks prior to randomization.
6. Patients using tumor necrosis factor α (TNFα) inhibitors must have experienced an inadequate response to the standard treatment doses for at least 3 months, or have been intolerant to anti-TNFα agents.
7. Patients who have previously been on a TNFα inhibitor will be allowed entry into study after an appropriate wash-out period prior to randomization (e.g., washout periods of 4 weeks for etanercept, 8 weeks for infliximab, and 10 weeks for adalimumab, golimumab, and certolizumab, respectively).
8. Patients taking Methotrexate (MTX) (≤ 25 mg/week) or sulfasalazine (SSZ) ( ≤ 3 g/day) are allowed to continue their medication and must have taken it for at least 3 months and be on a stable dose for at least 4 weeks prior to randomization. Patients taking MTX need to take folic acid supplements.
9. Patients who are on conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) other than MTX and sulfasalazine must discontinue the csDMARDs 4 weeks prior to randomization, except for leflunomide (LEF), which has to be discontinued for 8 weeks prior to randomization unless a cholestyramine washout has been performed.
10. Patients taking systemic corticosteroids have to be on a stable dose of ≤ 10 mg/day prednisone or equivalent for at least 2 weeks prior to randomization
Exclusion Criteria
2. Previous exposure to JS005 or any other biologic drug directly targeting IL-17 or IL-17 receptors.
3. Have taken high potency analgesics (e.g., opiates of methadone, hydromorphone, morphine) within 2 weeks prior to randomization.
4. Previous treatment with any intra-articular injection (e.g., glucocorticoids) within 4 weeks prior to randomization.
5. Previous treatment with any biological immunomodulating agents other than the TNFα inhibitors.
6. Treatment with JAK inhibitor agents within 8 weeks prior to randomization and unwilling to discontinue during the study.
7. Patient unwilling to take folic acid/leucovorin to reduce MTX toxicity.
8. Has received any cell-depletion therapies including but not limited to anti-CD20 antibodies, or investigational agents (e.g., Campath, anti-CD4 , anti-CD5, anti-CD3, anti-CD19).
9. Previous treatment with traditional Chinese medicine or animal and plant extracts for AS within 4 weeks prior to randomization.
10. Use of any investigational agents and/or devices within 4 weeks prior to randomization or within 5 half-lives of the investigational drug, whichever is longer.
11. Females who are pregnant or lactating.
12. Chest imaging (e.g., x-ray or CT) with evidence of ongoing infectious or malignancy, obtained within 3 months prior to screening and evaluated by a qualified physician
13. Active systemic infections (other than the common cold) within 2 weeks prior to randomization.
14. Patients with other diseases other than ankylosing spondylitis that might confound the evaluation of the efficacy of JS005 therapy: such as chronic pain other than ankylosing spondylitis (such as fibromyalgia), inflammatory bowel disease, acute anterior uveitis, etc., within 6 weeks prior to randomization. However, patients with non-acute iritis and psoriasis that have been stable for 6 months or more can be included in this study.
15. Underlying metabolic, hematologic, renal, hepatic, pulmonary, neurological, endocrine, cardiac, infectious, or gastrointestinal conditions which in the opinion of the investigator immunocompromises the patient and/or places the patient at unacceptable risk in case of using immunomodulatory therapy.
16. Myocardial infarction, apoplexy, congestive heart failure (New York Heart Association status of class III or IV) within 6 months prior to screening; uncontrolled hypertension (≥ 160/95 mmHg) prior to randomization.
17. Patients with type 1 diabetes mellitus, or newly diagnosed or uncontrolled type 2 diabetes mellitus (e.g., HbA1C \> 9.0%) within 6 months prior to screening.
18. Patients with active liver disease or hepatic insufficiency, with any of the following abnormalities in liver function tests at screening: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin \> 1.5 × upper limit of normal.
19. History of renal injury, glomerulonephritis, or patient with only one kidney or glomerular filtration rate \< 60 mL/(min · 1.73 m2 ) at screening.
20. Total white blood cell count \< 3 × 109/L, or neutrophils \< 1.5 × 109/L or absolute lymphocyte count \< 0.5 × 109/L or hemoglobin \< 8.5 g/dL or platelets \< 100 × 109/L at screening.
21. History of ongoing chronic or recurrent infectious disease, or evidence of tuberculosis infection on tuberculosis screening (X. DOT-TB, QuantiFERON TB-Gold, T-SPOT) (see Section 8.3.4 for details).
22. Positive for human immunodeficiency virus antibody (Anti-HIV) at screening.
23. Positive for hepatitis C virus antibody (Anti-HCV) at screening.
24. HBV DNA is detected in patients with positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) at screening (the lower limit of quantitative detection refers to the reference value of each hospital.).
25. History of lymphoproliferative disease or malignancy within the past 5 years (except for basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 3 months, and carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been surgically removed ).
26. Previous or medical history of other significant concomitant diseases that, in the judgment of the investigator, participation would not be in the best interest of the patient. These include, but are not limited to, cardiovascular disorder, nephropathy, neurological disease (including demyelinating disease), active infectious disease, endocrine disease, gastrointestinal disease, hepatobiliary disease, metabolic disease, pulmonary disease, non-malignant lymphoproliferative disease, or other lymphatic diseases.
27. Surgery of the spine or joint or other major surgery (e.g., aneurysmectomy, gastric ligation) within 3 months prior to randomization or planned during the study.
28. History or evidence of ongoing alcohol or drug abuse within 6 months prior to randomization.
29. The patient has a history of systemic hypersensitivity to any biological agent, excluding injection site reactions.
30. Vaccination with a live vaccine (live attenuated vaccine\*) and BCG vaccine within 12 weeks prior to randomization
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sponsor GmbH
OTHER
Shanghai Junshi Bioscience Co., Ltd.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anhui Provincial Hospital
Hefei, Anhui, China
Beijing University
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Xiamen University
Shamen, Fujian, China
Sun Yat-sen Memorial Sun Yat-sen University City: Guangzhou
Guangzhou, Guangdong, China
Nanfang Hospital of Nandang Medical University
Guangzhou, Guangdong, China
Shantou University Medical Collge No.1 Affiliated Hospital
Shantou, Guangdong, China
Pking University Shenzhen Hospital
Shenzhen, Guangdong, China
Shenzhen People's Hospital
Shenzhen, Gudong, China
Tianjin Medical University General Hospital
Tianjin, Hebei, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Tongji Hospital Tongji Medical college of HUST
Wuhan, Hubei, China
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
The Affilated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
The First Hospital of Jilin University
Changchun, Jilin, China
The Second Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China
Shengjing Hospital of China medical University
Shengyang, Liaoning, China
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Chuanbei Meidical College Affiliated Hospital
Nanchong, Sichuan, China
People's Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, Xinjiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JS005-003-II-AS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.